OncoCare Cancer Centre

What OncoCare Cancer Centre does

OncoCare Cancer Centre is a private Singapore oncology practice established in 2007. It provides subspecialized medical oncology to adult cancer patients across a broad set of tumour types, primarily through direct consultations at eight hospital-based clinics in Singapore. The detailed footprint spans Gleneagles, Mount Alvernia, Mount Elizabeth, Royal Square, and Thomson facilities; OncoCare reports 16 senior doctors, more than 40,000 patient visits per year, and patients from 33 nationalities. Source:.\n\nCore services include chemotherapy, immunotherapy, targeted therapy, hormonal therapy, diagnosis, palliative care, nutrition support, genetic counselling, clinical trials, and broader patient support. The centres operate within established hospitals with access to CT, MRI, PET/CT imaging, radiotherapy, and laboratory services. OncoCare reports participation in more than 60 clinical trials and 700 publications by its doctors. Revenue is generated through outpatient consultations, diagnostics, and treatment services, with quote-based pricing, direct billing through extensive local and international insurer panels, and support for MediShield and MediSave claims. Source:.\n\nOncoCare is part of the Tamarind Health integrated oncology platform. Tamarind Health completed its acquisition of TalkMED in September 2025, expanding the parent network to 36 outpatient and hospital-based centres across Singapore, Hong Kong, Malaysia, the Philippines, Vietnam, and Mainland China, with more than 500 doctors and staff and over 180,000 patient visits annually. This adds regional scale to OncoCare's Singapore practice, although the specific ownership stake and financial contribution of OncoCare within Tamarind Health are not disclosed.

Name

OncoCare Cancer Centre

Legal name

OncoCare Pte. Ltd.

Website

https://oncocare.sg

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

OncoCare Cancer Centre is a Singapore private oncology practice founded in 2007, providing subspecialized adult cancer diagnosis, treatment, clinical trials, genetic counselling, and supportive care through eight hospital-based clinics to local and international patients.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industry

Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK)

Keywords

• Medical oncology services
• Cancer treatment centre
• Subspecialised oncology care
• Clinical trials oncology
• Private cancer care

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices9 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Medical Consultations and Treatment Services: OncoCare generates revenue through outpatient consultations with subspecialized oncologists, diagnostic services, and cancer treatments including chemotherapy, immunotherapy, targeted therapy, hormonal therapy, and palliative care. Services are provided within established hospitals and medical centres.
2. Insurance and Government Scheme Billing: Direct billing arrangements with extensive insurance panels including local (Income, Prudential, Singlife, Raffles Health Insurance, AIA, Great Eastern, HSBC Life) and international insurers (Cigna, Aetna, Bupa, International SOS). Claims through MediShield and MediSave supported.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

OncoCare Cancer Centre is a Singapore-based private oncology practice that delivers subspecialised medical oncology care to adult cancer patients. It provides a comprehensive suite of cancer services including chemotherapy, immunotherapy, targeted therapy, hormonal therapy, cancer diagnostics, genetic counselling, palliative care, oncology nutrition support, and access to clinical trials, delivered by 16 senior doctors across nine clinic locations embedded within major Singapore hospitals. The practice operates under the Tamarind Health integrated oncology platform spanning 36 centres across Asia.

Product overview

OncoCare Cancer Centre is a Singapore-based oncology-focused healthcare provider (established 2007) operating under the Tamarind Health integrated platform. The centre offers a unified suite of cancer care services centred around subspecialised medical oncology. The core treatment services include Chemotherapy, Immunotherapy, Targeted Therapy, and Hormonal Therapy, supported by diagnostic services (Cancer Diagnosis), specialist services (Genetic Counselling), and supportive care (Palliative Care, Oncology Nutrition Support, Support Services). The centre also provides access to Clinical Trials and a Medical Concierge for patient navigation. OncoCare treats a broad portfolio of cancer types spanning genitourinary, blood, gastrointestinal, hepatobiliary, women's, CNS, head and neck, respiratory, and rare cancers. The centre operates eight Singapore clinic locations with a team of 16 senior doctors and participates in over 60 clinical trials. It is part of a regional network spanning Singapore, Hong Kong, Malaysia, the Philippines, Vietnam, and Mainland China under Tamarind Health.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemotherapy

Quantifiable outcome

• 40,000+ cancer patient visits per year
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Tamarind HealthcoreStrategic or Co-development Partner · 1 September 2025Tamarind Health completed its acquisition of TalkMED in September 2025, marking its next phase as Asia's leading integrated oncology-focused healthcare platform. OncoCare is part of this expanded network spanning 36 outpatient and hospital-based centres across Asia.
• Insurance Providers (Local Panel)coreChannel Partner/ Reseller/ DistributorDirect billing arrangements with extensive local insurance panel including Income, Prudential, Singlife, Raffles Health Insurance, AIA, Great Eastern, HSBC Life for streamlined claims processing.
• International Insurance ProviderscoreChannel Partner/ Reseller/ DistributorDirect billing and cashless payment arrangements with international insurers including Cigna, Aetna, Bupa, International SOS, MSH China, Now Health International, and others for international patients.
• Singapore Cancer SocietyminorOthersCommunity organization providing complementary support services for cancer patients in Singapore.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• National Cancer Centre Singapore (NCCS): NCCS is the largest public-sector cancer centre in Singapore, providing comprehensive oncology services and research under SingHealth. While not a direct private-sector competitor, it dominates cancer case volumes in Singapore and sets clinical benchmarks that OncoCare's private practice must match.
• Mount Elizabeth Oncology (IHH Healthcare): Mount Elizabeth hospitals, operated by IHH Healthcare, house both Parkway Cancer Centre and other oncology offerings, positioning them as a broad incumbent in Singapore private oncology. They compete with OncoCare for premium private cancer patients across multiple hospital campuses.

Emerging players

• HealthCare Global Enterprises (HCG): HCG is an India-headquartered oncology hospital chain with growing Asia presence, offering medical oncology, radiation oncology, and surgical oncology services. It is an emerging regional peer to OncoCare for cross-border oncology patients and the broader Tamarind Health network.

Regional players

• Subang Jaya Medical Centre (SJMC): SJMC is a major Malaysian private hospital with oncology services under Ramsay Sime Darby Health Care, operating in a different geography from OncoCare but serving overlapping Malaysian patient flows and competing within the broader Tamarind Health network catchment.
• Bumrungrad International Hospital: Bumrungrad International Hospital in Bangkok, Thailand is a leading medical tourism hospital with a dedicated oncology centre serving international patients across Southeast Asia. It is a regional peer competing with OncoCare for international patients seeking cancer treatment in Asia.
• Beacon Hospital (Malaysia): Beacon Hospital is a private specialty hospital in Petaling Jaya, Malaysia with a focused oncology centre offering medical oncology and radiotherapy. It is a regional peer to OncoCare operating in a neighbouring geography within Southeast Asia.

Direct peers

• Parkway Cancer Centre: Parkway Cancer Centre, part of IHH Healthcare, operates within Mount Elizabeth, Mount Elizabeth Novena, and Gleneagles hospitals in Singapore and offers comprehensive oncology services including medical oncology, radiotherapy, and stem cell transplant. It is a direct competitor to OncoCare for premium private cancer patients in the same hospital campuses.
• Raffles Cancer Centre: Raffles Cancer Centre, part of Raffles Medical Group, provides medical oncology, radiation oncology, and supportive care within Raffles Hospital in Singapore. It is a direct peer to OncoCare, competing for self-pay and insured private oncology patients in Singapore.
• Icon Cancer Centre: Icon Cancer Centre is a leading private oncology provider in Singapore offering medical oncology, radiation oncology, and haematology services within major private hospitals. It is a direct peer to OncoCare, competing for the same subspecialist talent, insurer panels, and international patient flows in Singapore.
• TalkMED (Tamarind Health): TalkMED is a Singapore private oncology practice that was acquired by Tamarind Health in September 2025 and is now a sister platform to OncoCare within the same parent network. It offers comparable medical oncology services and shares the Tamarind Health pan-Asian oncology platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@oncocaresingapore
• Facebookfacebook.com/OncoCareCancerCentreSingapore
• LinkedInlinkedin.com/company/oncocare-medical
• Instagraminstagram.com/oncocaresg

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncoCare Cancer Centre